1. Healthcare

  2. •

    Drug Manufacturers - Specialty & Generic
Argent BioPharma Limited

Argent BioPharma Limited

RGT.L
Argent BioPharma LimitedGB flagLondon Stock Exchange
6.00
GBp
-0.50
- -
4.18MMarket Cap
Argent BioPharma Limited
RGT.L
(London Stock Exchange)

Recent

price

6.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
FRC
42.06
43.6
- -
- -
- -
- -
- -
- -
0.12
0.26
0.54
1.5
1.55
1.84
1.15
- -
Revenue per Share
-244.97
-326.14
156.01
-11.25
-11.83
-33.37
-13.43
-10.2
-8.43
-7.33
-1.91
-14.01
-8.33
-7.93
-7.08
- -
Basic EPS, GAAP
-55.32
-131.1
-27.72
-14.68
-8.4
-2.96
-2.18
-5.54
-5.99
-0.41
-0.3
-0.7
-1.75
-1.05
-0.06
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
-1.11
-320.97
66.78
30.46
118.8
25.11
3.6
17.73
13.22
9.25
6.34
-1.43
3.42
-0.43
-5.26
- -
Book Value per Share
-55.75
-389.08
66.78
30.46
122.59
28.44
6.81
7.7
9.02
4.98
4.77
2.24
3.56
0.79
-2.73
- -
Tangible Book Value per Share
- -
- -
- -
- -
- -
- -
- -
1
1
1
1
1
2
3
3
- -
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
1
2
3
5
3
1
Sales/Revenue/Turnover
-988.99
-1,052.71
- -
- -
- -
- -
- -
- -
-6,087.36
-2,446.32
-1,377.42
-567.76
-407.37
-301.38
-460.46
-2,049.4
Operating Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
1
1
Depreciation Expense
-2
-3
2
- -
-1
-5
-4
-6
-8
-8
-2
-19
-16
-20
-21
-18
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
-582.4
-748.06
- -
- -
- -
- -
- -
- -
-6,773.31
-2,778.31
-351.91
-931.29
-535.62
-430
-614.71
-1,967.34
Profit Margin (%)
-2
-16
1
- -
- -
- -
- -
4
8
4
2
- -
3
-1
-11
-9
Working Capital
9
1
- -
- -
- -
- -
- -
- -
- -
- -
- -
2
2
2
- -
1
LT Debt
- -
-3
1
1
8
5
2
12
16
13
11
3
14
5
-8
-6
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
-36.01
-18.07
-91.12
-150.85
-105.05
-69.38
-71.14
-25.55
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
38.16%
-13.92%
-27.48%
Free Cash Flow
70.49%
54.65%
-26.2%
Net Income, GAAP
73%
147.03%
-15.81%
Sales/Revenue/Turnover
- -
43.39%
-73.7%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2022
- -
- -
- -
- -
5
2023
- -
- -
- -
- -
3
2024
- -
- -
- -
- -
1

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2022
- -
- -
- -
- -
-7.93
2023
- -
- -
- -
- -
-7.08
2024
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2022
- -
- -
- -
- -
- -
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
Similar Companies
Isracann Biosciences Inc. (IPOT.CN)
Dong Sung Bio Pharm.Co.,Ltd. (002210.KS)
Assertio Holdings, Inc. (ASRT)
Yuyu Pharma, Inc. (000227.KS)
Cann American Corp. (CNNA)
CMG Pharmaceutical Co., Ltd. (058820.KQ)
Business
Argent BioPharma Limited Argent BioPharma Limited (ASX:RGT; LSE:RGT.L) is a clinical-stage biopharmaceutical company that develops and markets innovative nano-engineered therapeutics targeting the central nervous system and autoimmune disorders; its pipeline includes CimetrA in phase IIB trials for acute lung injury and ARDS, CannEpil in phase I trials for refractory epilepsy, CogniCann in phase IIA trials for dementia and Alzheimer's symptomatic relief, preclinical Irnican for glioblastoma multiforme, and RGAI03MW01 for chronic wound treatment. The company employs advanced nanotechnology and polypharmacology via its in-house R&D platform to create multi-targeted therapies aimed at enhancing efficacy and reducing side effects, with investigational medicinal products accessible through early patient programs in the UK, USA, Europe, and Australia. Founded in 2014 and headquartered in Subiaco, Australia, Argent BioPharma operates globally with a focus on immunology and neurology, including cannabinoid-based APIs supplied to institutions like Slovenia's University Medical Centre Ljubljana for drug-resistant epilepsy and collaborations such as with SINTEF for antimicrobial wound therapies. In November 2025, the company secured an A$11 million financing facility from C/M Capital, enabling completion of its US$15 million acquisition of AusCann Group assets—including Neuvis oral drug delivery technology, CannPal's epilepsy data and IP, and an EU-GMP cannabinoid facility—while gaining a 19.99% stake in Germany's ECC Pharm for distribution access; this supports expansion into North and South America and a potential US dual listing. Recent leadership changes feature Roby Zomer transitioning to Non-Executive Chairman, Andrew Chapman appointed as Executive Director, and board adjustments including Gary Hermon's departure, positioning the firm for accelerated commercial development.